Clinical trials: Zidovudine
- Drug or intervention Zidovudine
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Healthy
Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fasting Conditions
The purpose of this study is to evaluate the relative bioavailability of the test formulation of Zidovudine 300 mg tablets with an already marketed reference formulation RETROVIR ® 300 mg tablets (GlaxoSmithKline), under fasted…
- Trial name
- NCT00779233
- Testing
- Zidovudine tablets 300 mg
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Ranbaxy Laboratories Limited
Healthy
Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir in Healthy Subjects
Study to determine the effect of BILR 355/r on Combivir® pharmacokinetics and the effect of Combivir® on BILR 355 BS pharmacokinetics.
- Trial name
- NCT02256774
- Testing
- BILR 355 BS, Combivir®, Ritonavir
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fed Conditions
The objective of this study was to assess the single-dose relative bioavailability of Ranbaxy and GlaxoSmithKline (Retrovir ®) 300 mg Zidovudine tablets, under fed conditions
- Trial name
- NCT00779376
- Testing
- Zidovudine 300mg tablets
- Where
- Canada
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Ranbaxy Laboratories Limited
Infection, Human Immunodeficiency Virus I
A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™
This is a study in healthy adult subjects to evaluate the bioequivalence of a Combined Formulated Tablet compared with maraviroc and Combivir administered concurrently versus maraviroc + Combivir.
- Trial name
- NCT01597648
- Testing
- Maraviroc, Combivir, GSK2838510
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
Bioequivalency Study of Zidovudine Under Fed Conditions
The objective of this study was to assess the bioequivalence of Roxane's zidovudine 300 mg tablet compared to GlaxoSmithKline's Retrovir® 300 mg tablet under fed conditions using a single-dose, randomized, 2-treatment, 2-period…
- Trial name
- NCT00601562
- Testing
- Zidovudine
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
HIV Infections
Bioequivalency Study of Zidovudine Under Fasting Conditions
The objective of this study was to assess the bioequivalence of Roxane's zidovudine 300 mg tablet compared to GlaxoSmithKline's Retrovir® 300 mg tablet under fasting conditions using a single-dose, randomized, 2-treatment…
- Trial name
- NCT00602550
- Testing
- Zidovudine
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
HIV Infections
A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus
To evaluate the safety and effectiveness of Retrovir (AZT) when used as prophylaxis for health care workers at risk for HIV infection from exposure to HIV-contaminated blood or blood components.
- Trial name
- NCT00002287
- Testing
- Zidovudine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Glaxo Wellcome
Healthy
Comparison of the Effect of Tipranavir and Ritonavir or Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Zidovudine in Healthy Volunteers
The objective of this study was to characterize the effect of two dose combinations of tipranavir/ritonavir (TPV 500 mg/RTV 100 mg and TPV 750 mg/RTV 200 mg) administered twice daily on the pharmacokinetics (PK) of zidovudine…
- Trial name
- NCT02249416
- Testing
- Tipranavir (TPV) low, Ritonavir (RTV) low, Tipranavir (TPV) high
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim